Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been given a consensus rating of “Buy” by the ten analysts that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.50.

A number of research analysts have issued reports on CATX shares. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, November 11th. UBS Group reiterated a “buy” rating and set a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 3rd. B. Riley reduced their target price on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Finally, BTIG Research initiated coverage on Perspective Therapeutics in a research report on Friday, October 10th. They set a “buy” rating and a $14.00 price target for the company.

Perspective Therapeutics Stock Down 5.2%

Perspective Therapeutics stock opened at $2.56 on Thursday. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average of $2.55 and a two-hundred day moving average of $3.13. Perspective Therapeutics has a one year low of $1.60 and a one year high of $5.39.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. Equities research analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of CATX. Vanguard Group Inc. raised its position in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after buying an additional 163,532 shares during the last quarter. Nicholson Wealth Management Group LLC increased its stake in shares of Perspective Therapeutics by 0.3% in the second quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock worth $5,553,000 after acquiring an additional 5,000 shares during the period. Geode Capital Management LLC raised its holdings in shares of Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after purchasing an additional 188,887 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Perspective Therapeutics by 139.9% during the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock worth $2,695,000 after purchasing an additional 458,323 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after purchasing an additional 405,612 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.